Amedeo's Top 20

Amedeo Smart

Independent Medical Education

21 September 2020

Multidisciplinary Journal Club

  1. Thomson MJ, Lok AS, Tapper EB.
    Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis.
    Hepatology 2020.

  1. Waterhouse DM, Garon EB, Chandler J, McCleod M, et al.
    Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
    J Clin Oncol 2020.

  2. Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, et al.
    Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
    Gastroenterology 2020;159:481-491.e3.

  3. Fralick M, Kim SC, Schneeweiss S, Everett BM, et al.
    Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study.
    BMJ 2020;370:m2812.

  4. Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, et al.
    Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial.
    J Clin Oncol 2020.

  1. de Jong JJ, Latenstein CSS, Boerma D, Hazebroek EJ, et al.
    Functional Dyspepsia and Irritable Bowel Syndrome are Highly Prevalent in Patients With Gallstones and are Negatively Associated With Outcomes After Cholecystectomy: A Prospective, Multicentre, Observational Study (PERFECT - Trial).
    Ann Surg 2020.

  2. Los-de Vries GT, De Boer M, van Dijk E, Stathi P, et al.
    Chromosome 20 loss is characteristic for Breast implant-Associated Anaplastic Large Cell Lymphoma.
    Blood 2020.

  3. Sprung CL, Joynt GM, Christian MD, Truog RD, et al.
    Adult ICU Triage During the Coronavirus Disease 2019 Pandemic: Who Will Live and Who Will Die? Recommendations to Improve Survival.
    Crit Care Med 2020;48:1196-1202.

  4. Jatoi I, Pinsky PF.
    Breast Cancer Screening Trials: Endpoints and Over-diagnosis.
    J Natl Cancer Inst 2020.

  5. Ortuno-Lizaran I, Sanchez-Saez X, Lax P, Serrano GE, et al.
    Dopaminergic retinal cell loss and visual dysfunction in Parkinson's disease.
    Ann Neurol 2020.

  1. Baumgartner H, Iung B, Otto CM.
    Timing of intervention in asymptomatic patients with valvular heart disease.
    Eur Heart J 2020.

  2. Razi SS, Kodia K, Alnajar A, Block MI, et al.
    Lobectomy Versus Stereotactic Body Radiotherapy In Healthy Octogenarians With Stage I Lung Cancer.
    Ann Thorac Surg 2020.

  3. Ogata H, Shimofurutani N, Okada T, Nagamoto H, et al.
    Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double-blind, randomized, placebo-controlled trial.
    Nephrol Dial Transplant 2020.

  4. Martin LF, Patwardhan AM, Jain SV, Salloum MM, et al.
    Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial.
    Cephalalgia 2020.

  5. Khan SA, Naz A, Qamar Masood M, Shah R, et al.
    Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia.
    Am J Cardiol 2020.

  1. Lu J, Zheng CH, Xu BB, Xie JW, et al.
    Assessment of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Controlled Trial.
    Ann Surg 2020.

  2. Elias ED, Targownik LE, Singh H, Bernstein CN, et al.
    A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD.
    Inflamm Bowel Dis 2020;26:150-157.

  3. Asano Y, Tajiri K, Yagishita S, Nakanishi H, et al.
    Bilateral atypical ulnar fractures occurring after long-term treatment with bisphosphonate for 7 years and with teriparatide for 2 years: a case report.
    Osteoporos Int 2020.

  4. Huthmacher JA, Meier JJ, Nauck MA.
    Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.
    Diabetes Care 2020;43:2303-2312.

  5. Chapuis-Biron C, Bourrier A, Nachury M, Nancey S, et al.
    Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients.
    Aliment Pharmacol Ther 2020;51:719-727.


more..

Privacy Policy